Columbia Laboratories (CBRX) Misses Q4 EPS by 12c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Columbia Laboratories Reports Fourth Quarter and Full-Year 2014 Financial Results
March 18, 2015 7:00 AM EDTBOSTON, March 18, 2015 /PRNewswire/ -- Columbia Laboratories, Inc. (Nasdaq: CBRX) ("Columbia" or the "Company"), today announced financial results for the three- and twelve-month periods ended December 31, 2014.Â
"The 11% growth in our 2014 full year revenues was driven in large part by a full year of service revenue, which helped offset the anticipated temporary decline in CRINONE® sales. During this transitional year we restarted our drug development activities, significantly strengthened our management team, and generated a substantial amount of cash," stated Frank Condella, CEO.
"Our strategy going forward is to utilize cash... More
